<bill session="113" type="s" number="1128" updated="2016-10-25T16:25:09Z">
  <state datetime="2013-06-11">REFERRED</state>
  <status>
    <introduced datetime="2013-06-11"/>
  </status>
  <introduced datetime="2013-06-11"/>
  <titles>
    <title type="short" as="introduced">Preserving Access to Orphan Drugs Act of 2013</title>
    <title type="official" as="introduced">A bill to clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers.</title>
    <title type="display">Preserving Access to Orphan Drugs Act of 2013</title>
  </titles>
  <sponsor bioguide_id="T000461"/>
  <cosponsors>
    <cosponsor bioguide_id="C000174" joined="2013-07-23"/>
    <cosponsor bioguide_id="C001070" joined="2013-06-11"/>
    <cosponsor bioguide_id="C000880" joined="2013-06-11"/>
    <cosponsor bioguide_id="M001169" joined="2014-06-26"/>
    <cosponsor bioguide_id="R000595" joined="2014-01-08"/>
    <cosponsor bioguide_id="W000437" joined="2013-07-24"/>
  </cosponsors>
  <actions>
    <action datetime="2013-06-11">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2013-06-11" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSFI" name="Senate Finance" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="113" relation="identical" number="2315"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Health care costs and insurance"/>
    <term name="Prescription drugs"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary date="2013-06-11T04:00:00Z" status="Introduced in Senate">Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.

Makes this Act effective as if included in PPACA.</summary>
  <committee-reports/>
</bill>
